Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.48 |
| ▸ | ADCY10 | Q96PN6 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PSD | A5PKW4 | 2/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25113428 | 0.87 | HSP90AB1 (0.54) | TACR1SLC6A4KCNH2ADCY10PSD | |
| SCHEMBL14458700 | 0.75 | TACR1 (0.40) | TACR1SLC6A4KCNH2KCNN3 | |
| SCHEMBL18379218 | 0.75 | TACR1 (0.40) | TACR1SLC6A4KCNH2ALDH1A1 | |
| SCHEMBL4018534 | 0.75 | TACR1 (0.40) | TACR1SLC6A4KCNH2KCNN3 | |
| SCHEMBL30092277 | 0.75 | TACR1 (0.40) | TACR1SLC6A4KCNH2ALDH1A1 | |
| SCHEMBL561528 | 0.75 | TACR1 (0.42) | TACR1SLC6A4KCNH2 | |
| SCHEMBL30498297 | 0.75 | TACR1 (0.40) | TACR1SLC6A4KCNH2KCNN3 | |
| SCHEMBL30048202 | 0.74 | HTR2B (0.47) | SLC6A4KCNN3 | |
| SCHEMBL18187028 | 0.74 | HTR2B (0.47) | SLC6A4KCNN3 | |
| Hydrochloric Acid SCHEMBL20400475 | 0.74 | TACR1 (0.40) | TACR1SLC6A4KCNH2KCNN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035372-A1 | METHOD FOR PRODUCING 2-HALOGENO-6-SUBSTITUTED-4-TRIFLUOROMETHYLPYRIDINE | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2012-02-09 | — | — | US | claimed |
| EP-2420492-A1 | METHOD FOR PRODUCING 2-HALOGENO-6-SUBSTITUTED-4-TRIFLUOROMETHYLPYRIDINE | Ishihara Sangyo Kaisha, Ltd. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120035372-A1 | METHOD FOR PRODUCING 2-HALOGENO-6-SUBSTITUTED-4-TRIFLUOROMETHYLPYRIDINE | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035372-A1 | METHOD FOR PRODUCING 2-HALOGENO-6-SUBSTITUTED-4-TRIFLUOROMETHYLPYRIDINE | RDX, CYP4X1, BRIX1 | TACR1 3293/4885SLC6A4 2198/4885KCNH2 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.